Sectors
CDT
CDT Equity Inc.
1.02
2 x 0.71
2 x 1.15
bid
ask
+
0.33
47.19%
2 @ 06:24 AM
1.47 +0.45 (44.12%)
| Ytd | -96.81% | |
| 1y | -99.78% |
0.87
day range
1.80
0.67
52 week range
610.00
| Open | 1.35 | Prev Close | 0.69 | Low | 0.87 | High | 1.80 | Mkt Cap | 4.96M |
| Vol | 249.47M | Avg Vol | 4.98M | EPS | -1177.89 | P/E | N/A | Forward P/E | N/A |
| Beta | 2.12 | Short Ratio | 0.14 | Inst. Own | 4.06% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 1.99 | 200-d Avg | 44.61 | 1yr Est | 0.00 |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|
Profile
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-06-10 | BLIGH JAMES | Chief Financial Officer | 37.27K | Stock Award(Grant) |
| 2024-11-17 | CHARLES FAITH L. | Director | 341.59K | Stock Award(Grant) |
| 2024-11-17 | FARLEY CHELE CHIAVACCI | Director | 351.51K | Stock Award(Grant) |
| 2023-09-21 | HEILBRON JACK KENDRICK | Former | 0.00 | Conversion of Exercise of derivative security |
| 2024-11-17 | LEWIS-HALL FREDA C | Director | 2.96M | Stock Award(Grant) |
| 2024-07-16 | REGAN ANDREW J. | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Barclays Plc | 837.83K | 45.66K | 0.70% |
| 2024-09-29 | Blackrock Inc. | 755.61K | 41.18K | 0.63% |
| 2024-09-29 | Geode Capital Management, LLC | 427.68K | 23.31K | 0.36% |
| 2024-09-29 | Vanguard Group Inc | 361.71K | 19.71K | 0.30% |
| 2024-09-29 | Qube Research & Technologies Ltd | 318.36K | 17.35K | 0.27% |
| 2024-09-29 | Citadel Advisors Llc | 189.99K | 10.35K | 0.16% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-08-30 | Fidelity Small Cap Index Fund | 233.35K | 12.72K | 0.19% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 202.93K | 11.06K | 0.17% |
| 2024-10-30 | iShares Micro Cap ETF | 111.58K | 6.08K | 0.09% |
| 2024-10-30 | iShares Russell 2000 Value ETF | 105.95K | 5.77K | 0.09% |
| 2024-10-30 | iShares Russell 2000 Growth ETF | 103.23K | 5.63K | 0.09% |
| 2024-08-30 | Vanguard Russell 2000 Index Fund | 92.76K | 5.06K | 0.08% |
Split
| Split | Date |
|---|---|
| 1 : 25 | 2026-03-27 |
| 1 : 8 | 2025-10-13 |
| 1 : 15 | 2025-05-20 |
| 1 : 100 | 2025-01-27 |
